159 related articles for article (PubMed ID: 19329941)
1. Glypican-3 expression in clear cell adenocarcinoma of the ovary.
Maeda D; Ota S; Takazawa Y; Aburatani H; Nakagawa S; Yano T; Taketani Y; Kodama T; Fukayama M
Mod Pathol; 2009 Jun; 22(6):824-32. PubMed ID: 19329941
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
3. "Piling up" clear cells in müllerian-type mucinous and mixed cell-type borderline tumor do not represent concomitant clear cell neoplasms.
Ohishi Y; Kurihara S; Aman M; Takeuchi T; Imamura H; Kaku T; Kobayashi H; Wake N; Oda Y
Hum Pathol; 2012 Oct; 43(10):1618-26. PubMed ID: 22436624
[TBL] [Abstract][Full Text] [Related]
4. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma.
Oe S; Hasegawa K; Nagase S; Kato R; Torii Y; Udagawa Y
Int J Gynecol Pathol; 2010 Sep; 29(5):405-10. PubMed ID: 20736762
[TBL] [Abstract][Full Text] [Related]
5. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
[TBL] [Abstract][Full Text] [Related]
6. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
Köbel M; Xu H; Bourne PA; Spaulding BO; Shih IeM; Mao TL; Soslow RA; Ewanowich CA; Kalloger SE; Mehl E; Lee CH; Huntsman D; Gilks CB
Mod Pathol; 2009 Mar; 22(3):469-75. PubMed ID: 19136932
[TBL] [Abstract][Full Text] [Related]
7. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
8. Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas.
Miller EM; Tymon-Rosario J; Sunkara J; Harmon BE; Karabakhtsian RG; Novetsky AP
Int J Gynecol Cancer; 2018 Sep; 28(7):1318-1324. PubMed ID: 30036224
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
[TBL] [Abstract][Full Text] [Related]
12. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.
Kwon AY; Heo I; Lee HJ; Kim G; Kang H; Heo JH; Kim TH; An HJ
Virchows Arch; 2016 May; 468(5):597-605. PubMed ID: 26951260
[TBL] [Abstract][Full Text] [Related]
13. Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
Nomura H; Tamada Y; Miyagi T; Suzuki A; Taira M; Suzuki N; Susumu N; Irimura T; Aoki D
Oncol Res; 2006; 16(6):289-97. PubMed ID: 17476974
[TBL] [Abstract][Full Text] [Related]
14. Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.
Maeda D; Chen X; Guan B; Nakagawa S; Yano T; Taketani Y; Fukayama M; Wang TL; Shih IeM
Int J Gynecol Pathol; 2011 Jan; 30(1):30-5. PubMed ID: 21131837
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 expression in primary and recurrent ovarian carcinomas.
Stadlmann S; Gueth U; Baumhoer D; Moch H; Terracciano L; Singer G
Int J Gynecol Pathol; 2007 Jul; 26(3):341-4. PubMed ID: 17581422
[TBL] [Abstract][Full Text] [Related]
16. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
[TBL] [Abstract][Full Text] [Related]
17. Napsin A is a specific marker for ovarian clear cell adenocarcinoma.
Yamashita Y; Nagasaka T; Naiki-Ito A; Sato S; Suzuki S; Toyokuni S; Ito M; Takahashi S
Mod Pathol; 2015 Jan; 28(1):111-7. PubMed ID: 24721826
[TBL] [Abstract][Full Text] [Related]
18. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
20. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
